205309-81-5
205309-81-5 結(jié)構(gòu)式
基本信息
中文別名
化合物 T11055 英文別名
DL-TBOABYOBCYXURWDEDS-IUCAKERBSA-N
D,L-THREO-B-BENZYLOXYASPARTATE
DL-threo-β-Benzyloxyasparticacid
DL-THREO-BETA-BENZYLOXYASPARTIC ACID
D-Aspartic acid, 3-(phenylmethoxy)-, (3R)-rel-
DL-TBOA價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-107522 | DL-TBOA DL-TBOA | 205309-81-5 | 5mg | 2900元 |
| 2024/11/08 | HY-107522 | DL-TBOA DL-TBOA | 205309-81-5 | 10mM * 1mLin DMSO | 3190元 |
| 2024/11/08 | HY-107522 | DL-TBOA DL-TBOA | 205309-81-5 | 10mg | 4500元 |
常見問(wèn)題列表
生物活性
DL-TBOA 是一種有效的不可運(yùn)輸?shù)呐d奮性氨基酸轉(zhuǎn)運(yùn)蛋白抑制劑，對(duì)興奮性氨基酸轉(zhuǎn)運(yùn)蛋白 1 (EAAT1)，EAAT2 和 EAAT3 的 IC50 值分別為 70 μM，6 μM 和 6 μM。DL-TBOA 抑制表達(dá)人 EAAT1 和 EAAT2 的 COS-1 細(xì)胞攝取 [14C]谷氨酸，Ki 值分別為 42 μM 和 5.7 μM。DL-TBOA 以競(jìng)爭(zhēng)性方式阻斷 EAAT4 和 EAAT5，Ki 值分別為 4.4 μM 和 3.2 μM。靶點(diǎn)
IC50: 70 μM (EAAT1), 6 μM (EAAT2) and 6 μM (EAAT3); Ki: 42 μM (human EAAT1), 5.7 μM (human EAAT2), 4.4 μM (EAAT4) and 3.2 μM (EAAT5)
體外研究
DL-TBOA (70-350 μM; 48 hours; HCT116 and LoVo cell lines) treatment concentration-dependently enhances SN38-induced loss of viability. DL-TBOA reversed Oxaliplatin-induced loss of viability.
DL-TBOA (350 μM; 24 hours; HCT116 and LoVo cell lines) treatment decreases p53 induction by SN38 and oxaliplatin.
Cell Viability Assay
| Cell Line: | HCT116 and LoVo cell lines |
| Concentration: | 70 μM, 350 μM |
| Incubation Time: | 48 hours |
| Result: | Enhanced SN38-induced, and counteracted Oxaliplatin-induced, cell death. |
Cell Viability Assay
| Cell Line: | HCT116 and LoVo cell lines |
| Concentration: | 350 μM |
| Incubation Time: | 24 hours |
| Result: | p53 induction by SN38 and oxaliplatin was decreased. |
體內(nèi)研究
DL-TBOA (10 nmol; i.c.v.) to morphine-dependent rats significantly facilitates the expression of naloxone-precipitated somatic signs and conditioned place aversion.
| Animal Model: | Male Sprague-Dawley rats (180-250 g) |
| Dosage: | 1 nmol, 3 nmol, 10 nmol |
| Administration: | Intracerebroventricularly injection (i.c.v.) |
| Result: | Dose dependently facilitated various somatic signs induced by Naloxone (0.1 mg/kg)-precipitated morphine withdrawal. |